---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-054995"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T12:00:00.947345+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio appoints Michael Grissinger to Board; Carl Gordon resigns

## Summary
- Carl L. Gordon resigned from Board and Compensation Committee effective April 17, 2025; no disagreement with management.
- Michael Grissinger appointed to Board and Compensation Committee, effective April 17, 2025, as Class II director until 2026 annual meeting.
- Grissinger received option to purchase 70,200 shares at April 17 closing price, vesting over 36 months.
- Grissinger brings 40+ years pharma experience, including 20+ years at Johnson & Johnson leading immunology licensing and M&A.
- He also serves on boards of Aprea Therapeutics (APRE) and three private biotechs.

## SEC filing metadata
- accession: 0000950170-25-054995
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/0000950170-25-054995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/acet-20250414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-054995
- JSON: https://secwatch.observer/filing/0000950170-25-054995.json
- Plain text: https://secwatch.observer/filing/0000950170-25-054995.txt

## Key facts
- Executive change
  Michael Grissinger was appointed as Director at Adicet Bio, Inc..
  - Action: appointed
  - Role: Director
  source text: On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/0000950170-25-054995-index.htm
- Executive change
  Carl L. Gordon resigned as Director at Adicet Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017025054995/0000950170-25-054995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.